Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset
Medicus Pharma Ltd. provided clarification on its Phase 2 clinical trial data for SkinJect, a doxorubicin-containing microneedle array for nodular basal cell carcinoma treatment. The company emphasized the therapeutic importance of the active drug arms over the device-only arm, highlighting that the 200µg dose cohort demonstrated the most promising…